• uPAR promotes cell associated proteolysis by binding to

  2021-12-30

  

  uPAR promotes cell-associated proteolysis by binding to uPA which locally converts plasminogen into active plasmin [10]. Ligand-engaged uPAR also acts as a potent regulator of cell migration and matrix attachment. Being a membrane receptor, uPAR needs to interact with extracellular matrix (ECM) prot

• A large body of literature have

  2021-12-30

  

  A large body of literature have reported that various cellular pathways are dysregulated in NPC [19]. Among these pathways, Akt is frequently hyperactivated in NPC and regulates diverse cellular processes including tumor cell growth, proliferation, metabolism, survival and invasion, as well as angio

• One limitation of our study was that all control dogs

  2021-12-30

  

  One limitation of our study was that all control dogs had histologic evidence of mild GI inflammation according to established WSAVA guidelines (Washabau et al., 2010), despite being apparently healthy purpose-bred research dogs housed in a controlled environment with no history of vomiting, diarrhe

• The more important effect of

  2021-12-30

  

  The more important effect of pitolisant is related to its wake-promoting and arousal activities as a result of enhanced Shikonin release in animal models (Ligneau, Perrin, et al., 2007). Moreover, its potential in the treatment of severe excessive daytime sleepiness (EDS) in narcoleptic teenagers re

• Based on the in vitro

  2021-12-30

  

  Based on the in vitro findings summarized here, we posited that, in the intact brain, release of ROS from iron-laden astrocytes to the local neuropil elicits oxidative damage and degeneration of indigent dopaminergic projections and other vulnerable neuronal elements (Schipper, 2001). Of particular

• br Conclusions br Acknowledgements This work was supported b

  2021-12-30

  

  Conclusions Acknowledgements This work was supported by grants from the Polish National Science Center: 2014/14/E/NZ1/00139 (to A. Jazwa-Kusior) and 2015/17/N/NZ1/00041 (to M. Tomczyk) and National Centre for Research and Development (STRATEGMED2/269415/11/NCBR/2015) (to J. Dulak). Faculty of

• br Transparency declaration br Acknowledgements br Hepatitis

  2021-12-30

  

  Transparency declaration Acknowledgements Hepatitis C Virus (HCV) infection represents a disease of significant global impact that afflicts around 170 million people worldwide., A small proportion of infected people clear the virus naturally, whilst the majority develop chronic hepatitis C (

• The discovery that the physiological functions of LPI are as

  2021-12-30

  

  The discovery that the physiological functions of LPI are associated with the activation of specific GPR55 membrane receptor [4] has launched a new era of research on this lysophospholipid. However, the activation of membrane receptors by lysophospholipids is extremely complex due to the multitude o

• In recent years several DPP

  2021-12-30

  

  In recent years, several DPP-IV inhibitors have already been approved, such as sitagliptin, vildagliptin, saxagliptin, tenegliptin, alogliptin and linagliptin, etc. Among them, linagliptin (1, Fig. 1) is a non-peptide mimetic glycerophosphate with a unique xanthine scaffold developed through high-th

• br Materials and methods br Results br Discussion ENU

  2021-12-30

  

  Materials and methods Results Discussion ENU mutagenesis is a powerful approach to identify novel genes or rho kinase inhibitor to dissect the molecular basis of mammalian immune system (Siggs, 2014). T cells are critical components in the host defense against pathogens, and their activity

• FPR family Human FPR was first defined biochemically in

  2021-12-29

  

  FPR family Human FPR was first defined biochemically, in 1976, as a high affinity binding site on the surface of neutrophils for the prototypic N-formyl peptide formyl-methionine-leucyl-phenylalanine (fMLF). It was then cloned in 1990, by Boulay et al. from a differentiated HL-60 myeloid leukemia-c

• The H R antagonist JNJ

  2021-12-29

  

  The H3R antagonist JNJ-17216498, developed by Johnson & Johnson, has entered clinical trial studies, but no information regarding its structure has been publicized to date. A phase II study of JNJ-17216498 monotherapy has been completed for patients with narcolepsy, but the results are not publicall

• AVL-292 Experimental conditions may be critical to explain o

  2021-12-29

  

  Experimental conditions may be critical to explain one model or the other. The matter of Hippo-driven cytoplasmic sequestration (Varelas et al., 2008) of active SMAD complexes (Varelas et al., 2008) vs. TßR basolateral relocalization upon epithelial polarization (Nallet-Staub et al., 2015) as mechan

• br Acknowledgments The authors gratefully acknowledge the

  2021-12-29

  

  Acknowledgments The authors gratefully acknowledge the financial support of this study by STCU Project 6052 “Enzyme multibiosensor system for renal dysfunction diagnosis and hemodialysis control”. Furthermore, this study was supported by NASU in the frame of Scientific and Technical Program “Sens

• br Discussion By using ultra deep sequencing

  2021-12-29

  

  Discussion By using ultra-deep sequencing, we conducted a thorough assessment of HCV-NS3 protease variants in chronic PI-naïve patients infected with HCV-1a and HCV-1b under telaprevir-based triple therapy at baseline and after 4weeks of treatment. Several synonymous and non-synonymous substituti

16721 records 559/1115 page Previous Next First page 上5页 556557558559560 下5页 Last page